AU2020311330A1 - Viral vector therapy - Google Patents
Viral vector therapy Download PDFInfo
- Publication number
- AU2020311330A1 AU2020311330A1 AU2020311330A AU2020311330A AU2020311330A1 AU 2020311330 A1 AU2020311330 A1 AU 2020311330A1 AU 2020311330 A AU2020311330 A AU 2020311330A AU 2020311330 A AU2020311330 A AU 2020311330A AU 2020311330 A1 AU2020311330 A1 AU 2020311330A1
- Authority
- AU
- Australia
- Prior art keywords
- gene therapy
- moiety
- compstatin analog
- compstatin
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962871058P | 2019-07-05 | 2019-07-05 | |
| US62/871,058 | 2019-07-05 | ||
| US201962871700P | 2019-07-08 | 2019-07-08 | |
| US62/871,700 | 2019-07-08 | ||
| US201962875925P | 2019-07-18 | 2019-07-18 | |
| US62/875,925 | 2019-07-18 | ||
| US201962935569P | 2019-11-14 | 2019-11-14 | |
| US62/935,569 | 2019-11-14 | ||
| PCT/US2020/040741 WO2021007111A1 (en) | 2019-07-05 | 2020-07-02 | Viral vector therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020311330A1 true AU2020311330A1 (en) | 2022-02-17 |
Family
ID=74114222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020311330A Pending AU2020311330A1 (en) | 2019-07-05 | 2020-07-02 | Viral vector therapy |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220249706A1 (https=) |
| EP (1) | EP3996744A4 (https=) |
| JP (1) | JP2022539238A (https=) |
| AU (1) | AU2020311330A1 (https=) |
| CA (1) | CA3143257A1 (https=) |
| WO (1) | WO2021007111A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11903994B2 (en) | 2015-10-07 | 2024-02-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens |
| IL269844B2 (en) * | 2017-04-07 | 2025-01-01 | Apellis Pharmaceuticals Inc | Dosage regimens and related compositions and methods |
| WO2019118938A1 (en) | 2017-12-15 | 2019-06-20 | Apellis Pharmaceuticals, Inc. | Dosing regimens and related compositions and methods |
| CN119264211A (zh) | 2018-08-27 | 2025-01-07 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| EP4346843A4 (en) * | 2021-05-27 | 2025-05-21 | Apellis Pharmaceuticals, Inc. | GENOME EDITING OF COMPLEMENT |
| CA3245921A1 (en) * | 2022-03-17 | 2023-09-21 | Adverum Biotechnologies, Inc. | Antibody Cassettes of Constituent 3 Anti-Complement, Vectorization and Therapeutic Application |
| CN120359233A (zh) * | 2022-11-24 | 2025-07-22 | 阿麦达斯制药美国有限责任公司 | 用于基于载体的疗法的坎普他汀类似物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000029033A2 (en) * | 1998-11-17 | 2000-05-25 | The General Hospital Corporation | A method of genetic vector delivery |
| JP2007112715A (ja) * | 2004-01-22 | 2007-05-10 | Dnavec Research Inc | 繰返し投与を伴うベクターの発現を継続させる方法 |
| MX366404B (es) * | 2012-11-15 | 2019-07-08 | Apellis Pharmaceuticals Inc | Analogos de compstatina de celula reactiva, de acción prolongada u objetivos y composiciones y metodos relacionados. |
| US10238700B2 (en) * | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
-
2020
- 2020-07-02 WO PCT/US2020/040741 patent/WO2021007111A1/en not_active Ceased
- 2020-07-02 AU AU2020311330A patent/AU2020311330A1/en active Pending
- 2020-07-02 CA CA3143257A patent/CA3143257A1/en active Pending
- 2020-07-02 JP JP2022500019A patent/JP2022539238A/ja active Pending
- 2020-07-02 EP EP20836586.6A patent/EP3996744A4/en active Pending
- 2020-07-02 US US17/624,755 patent/US20220249706A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3996744A1 (en) | 2022-05-18 |
| US20220249706A1 (en) | 2022-08-11 |
| WO2021007111A1 (en) | 2021-01-14 |
| JP2022539238A (ja) | 2022-09-07 |
| CA3143257A1 (en) | 2021-01-14 |
| EP3996744A4 (en) | 2023-07-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220249706A1 (en) | Viral vector therapy | |
| US20230009757A1 (en) | Combination therapy for c3 inhibition | |
| ES2877539T3 (es) | Acidos nucleicos que codifican secuencias repetitivas de aminoácidos ricos en residuos de prolina y alanina que tienen bajas secuencias de nucleótidos repetitivas | |
| US20250002910A1 (en) | Treatment of complement-mediated disorders | |
| JP6166041B2 (ja) | ミオチューブラリン1(mtm1)ポリペプチドを含むキメラポリペプチドを使用して筋細管ミオパシーを処置するための方法および組成物 | |
| KR20170116055A (ko) | 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도 | |
| US20220280598A1 (en) | Complement inhibitor dosing regimens | |
| KR102237306B1 (ko) | 옥심 결합을 위한 친핵성 촉매 | |
| TW201247709A (en) | Therapeutic proteins with increased half-life and methods of preparing same | |
| KR20220107243A (ko) | Apoe 유전자 요법 | |
| CA3170158A1 (en) | Rnas for complement inhibition | |
| US20250075209A1 (en) | Rnas for complement inhibition | |
| US12251395B2 (en) | RNAS for complement inhibition | |
| US20190100602A1 (en) | Anti-antithrombin single-domain antibodies and polypeptides comprising thereof | |
| US20230355660A1 (en) | Compound for the sequestration of undesirable anti-peg antibodies in a patient | |
| TWI922495B (zh) | 用以於一患者中螯合非預期的抗peg抗體的化合物 | |
| O'Donnell | Lipidic peptide dendrimers: Potential gene delivery agents for the treatment of haemophilia B | |
| Durigutto et al. | Prevention of Arthritis by Locally Synthesized Recombinant Antibody Neutralizing |